Monthly Archives: July 2009
Daiichi Sankyo Chief Talks Effient
FDA, late Friday, approved Daiichi Sankyo and Eli Lilly’s Effient (prasugrel), a blood thinner designed to lower the chance of blood clots in patients undergoing angioplasty. The drug received a black box warning from the get go, warning doctors of an increased risk of bleeding. However, the fact that the two companies now have a [...]
Posted in News, Strategy, Technology Tagged Clopidogrel, Daiichi Sankyo, effient, Eli Lilly and Company, EliLilly, Myocardial infarction, Plavix 2 Comments
Novo Nordisk Launches Branded Twitter Campaign
Novo Nordisk, last week, officially launched its branded Twitter site “Race with Insulin†to keep patients aware of the day-to-day happenings in the life of indie racer Charlie Kimball.
Using the social networking tool, Kimball openly talks about what it’s like to live with Type 1 diabetes and tweets about using Novo Nordisk’s Levemir (insulin detemir) [...]
Caraco Pharma Eliminates 350 Jobs
Caraco Pharmaceutical Labs announced on Monday that it will eliminate half its workforce—approximately 350 positions—but added that the number could grow as the generics firm deals with a voluntary manufacturing shutdown stemming from an FDA investigation.
Last month, US marshalls seized an undisclosed amount of drug ingredients and products in a raid at the company’s Michigan [...]
Posted in Strategy Tagged Bicalutamide, Caraco, Casodex, FDA, JPMorgan Chase, Manufacturing, Michigan, U.S. Food and Drug Administration, US 1 Comment

Pharma Accused of Keeping Good Generics Down